Latest News

4SC AG raises €41m

© 4SC AG


by tg

Small molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208

The company will raise €41m by offering 11,681,867 shares at €3.50 set to be listed on 13 July. The share capital of 4SC increased by approximately €11,68m to a total of €30,648,513. In 2017, 4SC’s capital raise is amongst the largest equity offerings in the biotech sector in Europe. The capital raised will finance 4SC through 2020. 4SC said it will facilitate the company’s development strategy for resminostat, 4SC-202 and 4SC-208.

Resminostat is an inhibitor of class I, IIb and IV HDACs, currently developed in cutaneous T-cell lymphoma (CTCL), Hodgkin’s lymphoma and lung, colon, pancreatic and biliary tract cancers as well as in hepatocellular cancer in combination with sorafenib. 4SC-202 is a blocker of histone deacetylase (HDAC) 1, 2, 3, and lysine-specific demethylase 1 (LSD1) clinically developed in different types of blood cancer.

4SC-208 is a small molecule targeting two kinases of  Hedgehog/GLI signaling pathway downstream of the regulator SMO at the level of GLI. Currently, 4SC is seeking approval for Phase I development of the compound designed to kill cancer stem cells.

CDPQ acquires stake in Sebia

CDPQ, whose assets total C$270bn, said the stake was „significant“. Headquartered in Lisses (near Paris, France), Sebia Group is a is the world’s...

Oxford Immunotec value drops after public offering

Oxford Immunotec said it will use the proceeds from the offering for working capital and general corporate purposes. The company’s immunodiagnostic...

Psoriasis: FDA approves guselkumab

The authorisation triggered an milestone payment from Janssen Biotech, Inc. to MorphoSys AG (Martinsried, Germany), which had discovered and licenced...

Diabetes: J&J and Seventure Partners launch investment

Seventure Partners said it ran the investment through its Health for Life Capital investment vehicle, as part of a $12m series A...

FMI to launch digital oncology service at Roche site

The new buildings, an overall investment of €600m over three years at the site, comprise expansions of Roche’s biomanufacturing facilities (a €330m...

Borreliosis vaccine receives FDA Fast Track Status

According to the Centers for Disease Control and Prevention (CDC), Lyme disease is the fastest growing vector-borne infectious disease in the United...

Germany is blocking EU Unitary Patent Court

According to the Court, a complaint (2 BvR 739/17) has been filed by an unnamed private person, which is “not wholly without merit”. The daily paper...